MYD88 and neoplasm: This data supports the interpretation that S100A9 in IMC-treated animals may contribute to neutrophil degranulation, TLR4 activation, and enhanced NF-κB-dependent transcriptional activity through MyD88, and promotion of an anti-tumor immune response.